Ahpra registration PHY0002298174
How these guides are written and reviewed →
Obesity hypoventilation syndrome (OHS) is when carrying a lot of extra weight makes breathing shallow enough that the body does not clear enough carbon dioxide, especially during sleep. Over time this leads to low oxygen and high carbon dioxide levels even when awake, causing tiredness, morning headaches, breathlessness and poor sleep. It is treatable — usually with a breathing machine at night (CPAP or BiPAP), weight management and physiotherapy. This page explains OHS and how we help.
Definition
Obesity hypoventilation syndrome (OHS) is defined by the combination of obesity (body mass index, BMI, ≥30 kg/m²), daytime hypercapnia — a raised arterial carbon dioxide tension (PaCO₂) above 45 mmHg — and sleep-disordered breathing, once other causes of hypoventilation have been excluded. It is a diagnosis of exclusion in that last respect: severe airflow obstruction, neuromuscular disease and chest-wall disorders must be ruled out first. Around 90% of people with OHS also have obstructive sleep apnoea (OSA), and the two conditions are best understood as overlapping rather than separate.
Pathophysiology
Three mechanisms combine, and none alone is sufficient to explain the syndrome.
Mechanical load. Adipose tissue on the chest wall and in the abdomen reduces chest wall compliance and pushes the diaphragm upwards, cutting functional residual capacity and expiratory reserve volume. Small airways at the lung bases close during tidal breathing, particularly when supine, producing ventilation–perfusion mismatch. The work of breathing rises substantially while the respiratory muscles operate at a mechanical disadvantage.
Blunted respiratory drive. Repetitive overnight hypoventilation allows carbon dioxide to accumulate faster than it can be cleared between events. The kidneys retain bicarbonate to buffer the resulting acidosis, and that metabolic compensation blunts the central chemoreceptor response to carbon dioxide. The system resets to tolerate a higher baseline, so hypercapnia persists into the day — the step that converts nocturnal hypoventilation into a chronic daytime syndrome. Leptin resistance is thought to contribute to this reduced drive.
Consequences. Chronic hypoxaemia and hypercapnia drive pulmonary vasoconstriction and remodelling, producing pulmonary hypertension and, in time, right ventricular strain and cor pulmonale. Fluid retention, polycythaemia and a high cardiovascular risk profile follow.1
Co-morbidities
OHS clusters with obstructive sleep apnoea, type 2 diabetes and metabolic syndrome, hypertension, heart failure, pulmonary hypertension, atrial fibrillation, gastro-oesophageal reflux, osteoarthritis and depression. These are not incidental: they both contribute to and result from the condition, and most patients are managed for several simultaneously. Perioperative risk is markedly elevated, and OHS is frequently first recognised during a surgical admission or in the recovery ward.
Prevalence
OHS is increasingly common as obesity becomes more prevalent. It is present in roughly 10–20% of people with obesity referred to sleep clinics, in around a third of those with a BMI above 40 kg/m² in hospital populations, and in a notable proportion of people diagnosed with OSA. It remains substantially under-recognised: a large share of patients are identified only after presenting acutely in hypercapnic respiratory failure, having had explicable symptoms for years.1
Causes and risk factors
- Obesity, particularly central and severe obesity — the underlying driver through the mechanical and control-of-breathing effects above.
- Coexisting obstructive sleep apnoea, especially when severe and untreated.
- Sedatives, opioids and alcohol, all of which further depress respiratory drive and are a common precipitant of acute decompensation.
- Supine sleeping position and rapid weight gain.
- Coexisting airflow obstruction — the overlap of obesity with COPD or asthma worsens gas exchange considerably.
- Respiratory muscle weakness or deconditioning, which reduces the reserve available to compensate.
Symptoms
Daytime symptoms
Excessive sleepiness and fatigue, morning headaches from overnight carbon dioxide retention, poor concentration and memory, low mood, and breathlessness on exertion and when lying flat. Sleepiness is often normalised by the patient over years and attributed to age, weight or work.
Night-time symptoms
Loud snoring, witnessed pauses in breathing, choking or gasping arousals, restless unrefreshing sleep, nocturia, and reflux. Partners frequently give a more accurate history than patients.
Signs of advanced disease
Ankle and leg swelling, a raised jugular venous pressure, polycythaemia, cyanosis and central obesity with a plethoric appearance — features of pulmonary hypertension and right-heart strain that indicate late presentation.
Signs of decompensation
Diagnosis
Why diagnosis matters
OHS is often diagnosed late, sometimes only after an admission with respiratory failure, and mortality in that group is high. Recognising it early allows night-time ventilation and weight management to begin before pulmonary hypertension and right-heart failure develop. The practical trigger for testing is straightforward: measure a bicarbonate or blood gas in anyone with obesity and unexplained daytime sleepiness, morning headache or breathlessness.2
How is it diagnosed?
Diagnosis requires demonstrating obesity, daytime hypercapnia and sleep-disordered breathing, and excluding other causes of hypoventilation. No single test achieves this, so the assessment is a sequence rather than one investigation.
Blood gases and bicarbonate
Arterial or capillary blood gases establish the daytime PaCO₂ and are the diagnostic requirement. A raised serum bicarbonate on a routine blood test is the practical screening clue — it reflects chronic renal compensation, is cheap and widely available, and a normal value makes OHS unlikely. Pulse oximetry alone cannot diagnose the condition, because it measures oxygen and the defining abnormality is carbon dioxide.
Sleep study
Overnight polysomnography with carbon dioxide monitoring, ideally transcutaneous, characterises the sleep-disordered breathing, distinguishes obstructive events from sustained hypoventilation, and quantifies nocturnal desaturation. Home studies without carbon dioxide monitoring will identify OSA but can miss hypoventilation entirely.
Lung function
Spirometry and lung volumes typically show a restrictive pattern with markedly reduced expiratory reserve volume and functional residual capacity, and a preserved or near-normal ratio of forced expiratory volume in one second to forced vital capacity. This step matters chiefly to exclude significant airflow obstruction or a neuromuscular cause; respiratory muscle pressures are measured where weakness is suspected.
Radiology and cardiac assessment
Chest imaging shows small lung volumes with basal atelectasis and helps exclude parenchymal disease. Echocardiography screens for pulmonary hypertension, right ventricular dilatation and coexisting left-heart disease, and an electrocardiogram may show right-heart changes or atrial fibrillation.
Investigations for related conditions
It is essential to distinguish OHS from other causes of hypoventilation — severe COPD, neuromuscular disease, kyphoscoliosis, hypothyroidism and drug-induced respiratory depression. Thyroid function, full blood count for polycythaemia, glucose or glycated haemoglobin, lipids, and kidney and liver function are checked, along with a medication review for sedatives and opioids.
Management
Management and goals
The goals are to correct nocturnal hypoventilation, normalise daytime carbon dioxide, relieve sleepiness and breathlessness, prevent and reverse pulmonary hypertension and right-heart strain, achieve sustained weight loss, and reduce cardiovascular and perioperative risk. Care is shared between the general practitioner, sleep and respiratory services, dietetics, physiotherapy and, where relevant, bariatric surgery.
Positive airway pressure
Night-time positive airway pressure is the cornerstone of treatment. CPAP is appropriate where OHS coexists with significant OSA; in the large Pickwick randomised trial, CPAP achieved long-term clinical outcomes comparable to non-invasive ventilation in that population, making it a reasonable and cheaper first choice for many.3 Bilevel ventilation (non-invasive ventilation, NIV) is used where carbon dioxide remains elevated despite CPAP, where there is little or no obstructive component, and in acute or acute-on-chronic hypercapnic failure. Earlier Pickwick analyses showed both modalities improve gas exchange, symptoms and lung function relative to lifestyle measures alone.4
Weight management
Weight loss addresses the cause rather than compensating for it, and sufficient loss can resolve hypoventilation entirely. Structured dietary and activity support is the foundation; pharmacotherapy is increasingly used; and bariatric surgery produces substantial and durable improvement in respiratory insufficiency, gas exchange and sleep-disordered breathing in selected patients.5 Positive airway pressure is continued through the weight-loss period and reassessed with repeat blood gases rather than stopped on assumption.
Oxygen — why it is not the answer alone
Supplemental oxygen without ventilatory support does not correct hypoventilation and can worsen carbon dioxide retention by reducing hypoxic respiratory drive and increasing dead space ventilation. Oxygen is used only alongside effective ventilation and with a target saturation range specified. This is a frequent and dangerous misunderstanding among patients and non-specialist staff, and correcting it is part of care.
Acute presentations
Acute-on-chronic hypercapnic respiratory failure is treated with NIV, treatment of the precipitant — commonly infection, sedatives, opioids or fluid overload — controlled oxygen to a specified target, and diuresis where there is right-heart failure. Admission is an opportunity, frequently the first, to establish long-term therapy before discharge.
Identifying deterioration
Increasing morning headache, returning daytime sleepiness, new or worsening ankle swelling, weight gain, reduced exercise tolerance or falling home oximetry readings all suggest inadequate ventilation and warrant review of adherence, mask fit, pressures and blood gases. New drowsiness or confusion is an emergency, not a review appointment.
Action plan
Each patient should know their prescribed pressures and usual settings, what to do if the mask fails or the machine breaks, their target oxygen saturation range, which symptoms mean urgent assessment, that sedatives and opioids need explicit discussion with the treating team before use, and that any hospital or surgical admission must be told about their diagnosis and therapy.
Medications
Medications for OHS
There is no specific drug therapy for the hypoventilation itself; treatment is ventilation and weight. Diuretics are used for fluid overload and right-heart failure, and coexisting conditions — hypertension, diabetes, heart failure, airflow obstruction — are treated on their own merits. See NIV: CPAP and BiPAP for the ventilatory modes.
Medicines to use with caution
Benzodiazepines, sedating antihistamines, gabapentinoids, opioids and alcohol all depress respiratory drive and are a common cause of decompensation. Where they are genuinely needed — peri-operatively, or for pain — they are used at the lowest effective dose with monitoring and established ventilatory support. Perioperative anaesthetic review should be flagged in advance rather than discovered on the day.
Weight-management pharmacotherapy
Pharmacological weight management is now part of standard obesity care and is used within a broader programme of dietary, activity and behavioural support rather than instead of it. Availability, indications and subsidy change frequently — verify current TGA and PBS status. Improvements in gas exchange follow weight loss and should be confirmed with repeat measurement.
Multi-system manifestations
Heart and circulation
Pulmonary hypertension, right ventricular dilatation and cor pulmonale from chronic hypoxaemia; systemic hypertension, left ventricular hypertrophy, heart failure with preserved ejection fraction, and a raised risk of atrial fibrillation and cardiovascular death.
Metabolic
Insulin resistance, type 2 diabetes, dyslipidaemia and non-alcoholic fatty liver disease, all interacting with the obesity that drives the syndrome and all improved by the same weight loss.
Kidneys and fluid balance
Chronic renal bicarbonate retention is central to the pathophysiology. Fluid retention, dependent oedema and, with coexisting diabetes and hypertension, chronic kidney disease are common.
Brain, mood and cognition
Chronic hypoxaemia, sleep fragmentation and hypercapnia impair attention, memory and executive function, and depression and anxiety are markedly more common than in obesity without OHS. Excessive sleepiness carries a significant motor vehicle and workplace accident risk that must be discussed and, where required, reported.
Perioperative and airway risk
Difficult airway, opioid sensitivity, higher rates of postoperative respiratory failure, unplanned intensive care admission and longer stay. Identifying OHS before elective surgery, and continuing home therapy through the admission, materially changes outcomes.
Musculoskeletal
Osteoarthritis of the knees, hips and spine, chronic low back pain, reduced mobility and deconditioning — a reinforcing loop with the weight gain and inactivity that drive the syndrome, and the point at which physiotherapy has most to offer.6
Living with obesity hypoventilation syndrome
Using therapy every night
Benefit tracks closely with hours of use, and most of the gain comes from consistent nightly use rather than perfect pressures. Mask discomfort, claustrophobia, nasal congestion, dry mouth, air leak and pressure marks are all solvable, and early proactive troubleshooting in the first weeks is what determines long-term adherence.
Nutrition and weight
Sustained modest weight loss improves gas exchange, sleep-disordered breathing and symptoms, and dietetic involvement makes success considerably more likely. Realistic staged goals work better than a target weight, and progress is best judged by symptoms, bicarbonate and exercise tolerance as well as the scales.
Sleep and positioning
Side sleeping and modest head-of-bed elevation reduce the mechanical load of obesity on the diaphragm and improve overnight oxygenation. Consistent sleep timing, and avoiding alcohol in the evening, both matter more here than in the general population.
Exercise and activity
Exercise capacity is markedly reduced, and exercise training added to positive airway pressure improves it further than therapy alone.7 Activity is prescribed rather than recommended — graded, supervised initially, using pacing, positions of ease and interval-style work, with attention to joint loading. Water-based and seated options are useful where weight-bearing is limiting.
Travel and daily life
Devices travel as medical equipment with appropriate documentation, plus a power adaptor and a plan for altitude. Vaccination for influenza, COVID-19 and pneumococcus is important given respiratory reserve, and any new prescription or hospital admission needs the diagnosis disclosed.
Driving and sleepiness
Untreated sleepiness affects driving safety and carries legal obligations in Australia, particularly for commercial drivers. It is discussed openly and revisited once therapy is established, when most patients improve substantially.
Prognosis
Untreated OHS carries a high risk of progressive respiratory failure, cardiovascular events, hospitalisation and death, with mortality considerably above that of obesity or OSA alone — and worse again after an admission with acute hypercapnic failure. With night-time ventilation and weight loss, symptoms, gas exchange, pulmonary artery pressures, quality of life and survival all improve substantially. Adherence to therapy and sustained weight management are the two main determinants of long-term outcome, which is why both are worth investing clinical time in.
Role of the physiotherapist
Physiotherapy contributes across three areas. The first is establishing and sustaining ventilation: mask selection and fit, desensitisation for claustrophobia, positioning, coordinating breathing with the device, troubleshooting leak and dry mouth, and the practical education that turns a prescription into nightly use (see NIV: CPAP and BiPAP). In many services this is the physiotherapist's work, and it is the intervention with the largest effect on outcome.
The second is exercise and rehabilitation. Individually graded cardiorespiratory rehabilitation improves exercise capacity, breathlessness and function beyond what positive airway pressure achieves alone,7 and supports weight management. Prescription accounts for joint loading, positions of ease, pacing and interval work, and progresses on tolerance rather than a fixed protocol.
The third is breathing and airway management: breathing retraining for the shallow, rapid, apical pattern that is common here, inspiratory muscle training in selected patients, positioning and airway clearance where secretions or basal atelectasis are a problem, and postoperative respiratory care, where this group is at high risk. Perioperatively, the physiotherapist is often the person who ensures home therapy is available on the ward from the first night.
Part 1 · References
- Chau EHL, Lam D, Wong J, Mokhlesi B, Chung F. Obesity hypoventilation syndrome: a review of epidemiology, pathophysiology, and perioperative considerations. Anesthesiology 2012;117(1):188–205.
- Mokhlesi B, Masa JF, Brozek JL, et al. Evaluation and management of obesity hypoventilation syndrome: an official American Thoracic Society clinical practice guideline. Am J Respir Crit Care Med 2019;200(3):e6–e24.
- Masa JF, Mokhlesi B, Benitez I, et al. Long-term clinical effectiveness of continuous positive airway pressure therapy versus non-invasive ventilation therapy in patients with obesity hypoventilation syndrome (Pickwick): a multicentre, open-label, randomised controlled trial. Lancet 2019;393(10182):1721–1732.
- Masa JF, Corral J, Alonso ML, et al. Efficacy of different treatment alternatives for obesity hypoventilation syndrome: Pickwick study. Am J Respir Crit Care Med 2015;192(1):86–95.
- Sugerman HJ, Fairman RP, Sood RK, Engle K, Wolfe L, Kellum JM. Long-term effects of gastric surgery for treating respiratory insufficiency of obesity. Am J Clin Nutr 1992;55(2 Suppl):597S–601S.
- Piper AJ, Grunstein RR. Obesity hypoventilation syndrome: mechanisms and management. Am J Respir Crit Care Med 2011;183(3):292–298.
- Mendelson M, Marillier M, Bailly S, et al. Maximal exercise capacity in patients with obstructive sleep apnoea and obesity hypoventilation: effects of exercise training added to positive airway pressure. Eur Respir J 2018;52(2):1702123.
References are numbered in citation order (Vancouver/BMJ style) and were current at the time of writing. Guidelines are living documents — verify against the latest version before clinical use.
More than one of our services applies here, and which combination suits you depends on what your assessment shows.
Clinical evidence
Part 1 covers the same condition without the technical detail. What follows is the evidence base behind it, written for clinicians — the literature, the reasoning and the gaps.
For clinicians: this summary supports clinical reasoning and is not a protocol. Check current guidelines and local policy before applying it, and read it alongside the key references and guidelines directory.
Framing. Obesity hypoventilation syndrome is defined by obesity, daytime hypercapnia (PaCO2 > 45 mmHg) and sleep-disordered breathing after other causes are excluded, and it is routinely diagnosed late — often during an acute hypercapnic admission, by which point mortality and readmission risk are high.1 The ATS guideline suggests screening obese patients with sleep-disordered breathing using serum bicarbonate, which is the cheapest high-yield action available in a physiotherapy setting where blood gases are not.1
Ventilatory support and weight
- CPAP is non-inferior to non-invasive ventilation in stable ambulatory OHS with severe concurrent obstructive sleep apnoea (Pickwick), so most stable patients can be managed on CPAP — a major simplification of the historical position.2
- Non-invasive ventilation remains first choice where there is no severe OSA, where hypercapnia is marked, or after an episode of acute-on-chronic hypercapnic failure.1,3
- Positive-pressure therapy plus lifestyle intervention outperforms lifestyle alone for gas exchange, symptoms and hospital use.3
- Weight loss is disease-modifying: a 25–30% total weight reduction can resolve hypoventilation, and bariatric surgery produces durable improvement in gas exchange and sleep-disordered breathing.4
- Untreated OHS carries substantially higher mortality than equally obese patients without hypoventilation, and discharge without a ventilatory and weight plan is a missed opportunity with measurable consequences.1,5
Mechanics and rehabilitation
- The mechanical problem is load plus reduced compliance: low functional residual capacity and expiratory reserve volume, basal airway closure, supine worsening and blunted ventilatory drive combine to produce hypoventilation that is worst in sleep and in the supine position.5
- Pulmonary rehabilitation added to positive-pressure therapy improves exercise capacity and quality of life in obesity-related respiratory disease, and exercise plus CPAP outperforms CPAP alone.6
- Postoperative pulmonary complications are markedly increased in these patients, so preoperative identification, CPAP or NIV continuation and structured postoperative respiratory care matter.7
- Opioid and sedative sensitivity is a specific hazard: ventilatory drive is already blunted, and perioperative or palliative opioid dosing needs caution and monitoring.1,7
Physiotherapy implications
- Screen actively: BMI over 30 with daytime sleepiness, morning headaches, ankle oedema, resting hypoxaemia or a raised bicarbonate should trigger referral for sleep and gas-exchange assessment.1
- Position deliberately: upright or high side-lying rather than supine for treatment and rest, and expect saturation to fall substantially when the patient lies flat.
- Support adherence to CPAP or NIV — mask fit, pressure tolerance, claustrophobia, mouth leak and humidification are the practical determinants of whether treatment works, and physiotherapists are well placed to troubleshoot them.2
- Train despite the load: combine walking or cycling intervals with progressive resistance work, use seated and water-based options where weight-bearing is limiting, and set expectations that fitness improves before weight does.6
- Recognise this is not primarily a secretion problem; airway clearance is only indicated for a coexisting suppurative or post-operative retention problem, while lung-volume recruitment and positioning are the mainstays.
- Escalate morning headache with confusion or drowsiness, rising oxygen requirement, worsening oedema or a fall in respiratory rate with increasing effort — these suggest decompensating hypercapnia and are an emergency.
- Coordinate the whole plan: sleep service, dietetics, GP, and increasingly weight-management pharmacotherapy or bariatric referral — physiotherapy alone will not fix the mechanics.4
Clinical reasoning
- Breathlessness in obesity is not automatically OHS — distinguish deconditioning, asthma, heart failure and hypoventilation, because only the last needs ventilatory support.
- A patient who desaturates on lying flat, is sleepy by day and has a raised bicarbonate has hypoventilation until proven otherwise.1
- Oxygen alone can worsen hypercapnia; the treatment for hypoventilation is ventilation, not more oxygen.3
- Frame weight management as a respiratory treatment with a defined target, because the threshold for resolution is a number rather than an aspiration.4
Evidence gaps
- No trial defines the optimal exercise prescription in OHS specifically, as opposed to obesity or OSA populations.6
- Long-term outcomes after switching from NIV to CPAP outside the Pickwick population are uncertain.2
- The place of incretin-based weight-loss pharmacotherapy in OHS, including whether it can replace ventilatory support, has not been established.
- Optimal follow-up interval and de-escalation criteria after substantial weight loss remain undefined.
References for the clinical evidence summary
- Mokhlesi B, Masa JF, Brozek JL, et al. Evaluation and management of obesity hypoventilation syndrome: an official American Thoracic Society clinical practice guideline. Am J Respir Crit Care Med 2019;200(3):e6–e24.
- Masa JF, Mokhlesi B, Benitez I, et al. Long-term clinical effectiveness of continuous positive airway pressure therapy versus non-invasive ventilation therapy in patients with obesity hypoventilation syndrome (Pickwick): a multicentre, open-label, randomised controlled trial. Lancet 2019;393(10182):1721–1732.
- Masa JF, Corral J, Alonso ML, et al. Efficacy of different treatment alternatives for obesity hypoventilation syndrome: Pickwick study. Am J Respir Crit Care Med 2015;192(1):86–95.
- Sugerman HJ, Fairman RP, Sood RK, Engle K, Wolfe L, Kellum JM. Long-term effects of gastric surgery for treating respiratory insufficiency of obesity. Am J Clin Nutr 1992;55(2 Suppl):597S–601S.
- Piper AJ, Grunstein RR. Obesity hypoventilation syndrome: mechanisms and management. Am J Respir Crit Care Med 2011;183(3):292–298.
- Mendelson M, Marillier M, Bailly S, et al. Maximal exercise capacity in patients with obstructive sleep apnoea and obesity hypoventilation: effects of exercise training added to positive airway pressure. Eur Respir J 2018;52(2):1702123.
- Chau EHL, Lam D, Wong J, Mokhlesi B, Chung F. Obesity hypoventilation syndrome: a review of epidemiology, pathophysiology, and perioperative considerations. Anesthesiology 2012;117(1):188–205.
Corrections: If something on this page is wrong, out of date or unclear, we want to know. Email reception@inspireclinic.au with the page name and what you believe is incorrect. Substantive corrections are made promptly, and the guide’s version and last-updated date are changed to reflect it.